Stereotactic Radiotherapy
Stereotactic Radiotherapy is a radiation therapy with 42 clinical trials. Currently 11 active trials ongoing. Historical success rate of 75.0%.
Success Metrics
Based on 9 completed trials
Phase Distribution
Phase Distribution
6
Early Stage
11
Mid Stage
2
Late Stage
Highest Phase Reached
Phase 3Trial Status & Enrollment
64.3%
9 of 14 finished
35.7%
5 ended early
11
trials recruiting
42
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
A Study to Assess the Ability of Stereotactic Radiotherapy to Restore the Efficacy of Immunotherapy in Patients With Metastatic Cancer.
Study Comparing Neoadjuvant Versus Adjuvant Stereotactic Radiotherapy of Brain Metastases
Veterans Affairs Lung Cancer Surgery Or Stereotactic Radiotherapy
Anti-PD 1 Brain Collaboration + Radiotherapy Extension (ABC-X Study)
Furmonertinib Combined With Intrathecal Chemotherapy and Stereotactic Radiotherapy (SRT) for EGFR-Mutated NSCLC Patients With Brain Parenchymal and Leptomeningeal Metastases
Clinical Trials (42)
A Study to Assess the Ability of Stereotactic Radiotherapy to Restore the Efficacy of Immunotherapy in Patients With Metastatic Cancer.
Study Comparing Neoadjuvant Versus Adjuvant Stereotactic Radiotherapy of Brain Metastases
Veterans Affairs Lung Cancer Surgery Or Stereotactic Radiotherapy
Anti-PD 1 Brain Collaboration + Radiotherapy Extension (ABC-X Study)
Furmonertinib Combined With Intrathecal Chemotherapy and Stereotactic Radiotherapy (SRT) for EGFR-Mutated NSCLC Patients With Brain Parenchymal and Leptomeningeal Metastases
Lu-PSMA and Stereotactic Radiotherapy Versus Radiotherapy Alone for Prostate Cancer (LUST)
SRS for NSCLC With Oligo-residual Intracranial Disease After First-line 3rd Generation EGFR-TKI
Stereotactic Radiotherapy Combined With Chemotherapy or Not for Treatment of Oligometastases in HNSCC
Conformal Partial Breast Irradiation With CyberKnife After Resection for Early Stage Breast Cancer
Stereotactic Radiotherapy of Prostate Cancer With Reduction of Safety Margins
Study of Osimertinib + SRS vs Osimertinib Alone for Brain Metastases in EGFR Positive Patients With NSCLC
STR + Anti PD-1 Therapy in Patients with Locally Advanced Unresectable Pancreatic Adenocarcinoma
Local Ablative Therapy for Patients With Multiple (4-10) Brain Metastases
Immunosensitized Radiotherapy Combined With Evoximab (AK112) and Chemotherapy Neoadjuvant Therapy for Stage II-III Non-small Cell Lung Cancer
Efficacy and Safety of SBRT Combined With Cardonilizumab and Lenvastinib in the Treatment of Unresectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus
Cardiac RadiothErapy for VEntricular Tachycardia
WHOle Brain Irradiation or STEreotactic Radiosurgery for Five or More Brain Metastases (WHOBI-STER)
Preoperative Radiotherapy in Patients at High Risk of Postoperative Pancreatic Fistula After Pancreatoduodenectomy
Neoadjuvant Chemotherapy and Stereotactic Radiosurgery to Pancreatectomy for Patients With Borderline Resectable Pancreatic Cancer
Stereotactic Radiotherapy for Brain Metastases
Drug Details
- Intervention Type
- RADIATION
- Total Trials
- 42